Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT

Completed

• Conditions: Refractory B-Cell Non-Hodgkin Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma

• Registration Number: NCT02992223
• Lead Sponsor: A.O.U. Città della Salute e della Scienza

Brief Summary

Evaluate if Y90 Ibritumomab Tiuxetan Radioimmunotherapy in addition to standard high dose chemotherapy followed by autologous stem cell transplant could improve prognosis in patients affected by relapsed/refractory aggressive non Hodgkin lymphoma

Detailed Description

Not available

Study Timeline

• Study Start: 2014-07
• Primary Completion: 2015-07
• Study Completion: 2015-07
• Status Verified: 2016-12
• Study First Submitted: 2016-12-12
• Study First Submitted QC: 2016-12-12
• Last Update Submitted: 2016-12-12
• Study First Posted: 2016-12-14
• Last Update Posted: 2016-12-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

• High Risk Relapsed/refractory aggressive non-hodgkin lymphoma defined as:
• Progressive disease
• Early relapse (within 12 months from response)
• Recurrent relapse
• Treated with salvage chemotherapy followed by Y90 Ibritumomab Tiuxetan plus high-dose chemotherapy and Autologous stem cell transplant
• Age > 18 years
• Previous treatment with Rituximab
• Written informed consent

Exclusion Criteria

• Patient with no complete data available for collection

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall Survival	Date of last follow-up for at least 18 months (up to 78 months)	Time to last follow-up or death
Progression Free Survival	From first response to last follow-up for at least 18 month (up to 78 months)	Time from last response to nearest relapse or follow-up